



Biotech Daily

Tuesday June 12, 2012

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH DOWN: USCOM UP 30%; CIRCADIANT, PRIMA DOWN 12%**
- * **MEDICINES AUSTRALIA TO FORUM: DRUGS ARE POST-MINING FUTURE**
- * **CIRCADIANT PLACEMENT RAISES \$1m AT 7% PREMIUM**
- * **RICHARD CARREON REPLACES IMPEDIMED CEO GREG BROWN**
- * **CHAIRMAN ANDREW KROGER TAKES 20% OF CRYOSITE**
- * **ATCOR REQUESTS CAPITAL RAISING TRADING HALT**

MARKET REPORT

The Australian stock market climbed 0.23 percent on Tuesday June 12, 2012 with the S&P ASX 200 up 9.2 points to 4,072.9 points.

Thirteen of the Biotech Daily Top 40 stocks were up, 15 fell, 10 traded unchanged and two were untraded.

Uscom was the best, up 2.1 cents or 30.4 percent to nine cents with 62,500 shares traded.

Allied Health and Benitec climbed more than five percent; Bioniche and Heartware were up more than four percent; Impedimed was up 3.45 percent; Sirtex rose 2.8 percent; Acrux, Anteo, Compumedics, CSL and Pharmaxis were up more than one percent; with QRX and Reva up by less than one percent.

Circadian and Prima led the falls, both down 11.5 percent to 46 cents and 11.5 cents, respectively, with 2,000 shares and 12 million shares traded, respectively.

Avita lost 7.1 percent; Phosphagenics fell 6.7 percent; Antisense and Living Cell were down more than five percent; Clinuvel, Genetic Technologies, Psivida and Sunshine Heart fell four percent or more; Alchemia, Ellex and Viralytics were down more than three percent; Starpharma 2.1 percent; Optiscan was down 1.2 percent; with Cochlear and Resmed down by less than one percent.

MEDICINES AUSTRALIA

Medicines Australia says the medicines industry “can offer the Australian economy significant competitive advantages in a post-mining boom future”.

A Medicines Australia media release said that chief executive Dr Brendan Shaw would attend tomorrow’s Economic Forum in Brisbane called by Prime Minister Julia Gillard.

Dr Shaw said that the medicines industry “is well positioned to help secure the future of Australia’s innovative manufacturing base”.

“We can develop this industry even further into one of the key Australian high-tech industries to help set up a post mining-boom economy, but we do need the right policy settings to encourage innovation, research and manufacturing,” Dr Shaw said.

“At a time when Australia is debating the economic value of manufacturing in this country, we have an industry that already delivers so much to the community and economy through jobs, skills, wages, exports and [research and development],” Dr Shaw said.

“With some key reforms the medicines industry will be able to continue contributing substantially to sustainable economic growth, driving global investment and supporting high-wage jobs,” Dr Shaw said.

“But we need to ensure Australia is more globally competitive, that we have a stable business environment, and that innovation is valued and supported,” he said.

“We have the people, the skills, the ideas, the research, the infrastructure, the companies, the experience and the critical mass to take the next steps and make Australia a key niche player in the global medicines industry,” Dr Shaw said.

“The opportunities from the innovative industry, the generics industry and the emerging biotech industry are there if Australia wants to capitalize on their potential,” Dr Shaw said.

Dr Shaw said the Australian medicines industry was already making a substantial contribution to the economy and capitalizing on Asian growth including the Glaxosmithkline \$60 million investment in Victoria to supply markets in Asia as well as a global supply of influenza medicines and in 2011, Astrazeneca Australia announced it would revitalize and upgrade its manufacturing plant in Sydney to supply the Chinese market with asthma medicines.

Medicines Australia said that CSL was expanding its biologic research and development facilities in Melbourne; IDT exported active ingredients for cancer medicines to companies all over the world; Australia supplied “a quarter of all poppies required to make medicinal opiates, largely sourced from Tasmania”; and the Danish company Leo Pharma had production facilities in Queensland manufacture active ingredients for skin conditions.

“These are exciting innovations that will deliver economic value to Australia, with improved policy settings and real support for innovation,” Dr Shaw said.

CIRCADIAN TECHNOLOGIES

Circadian says it has raised \$1.02 million through the placement of 2,084,714 shares at 49 cents, a seven percent premium to the 30-day volume weighted average price.

The company said that the private placement to institutional and sophisticated investors raised funds to support the ongoing development of its lead human antibody against vascular endothelial growth factor (VEGF) C, VGX-100, in both the oncology and ophthalmology.

Circadian said the funds would support manufacturing costs of material for phase II oncology clinical trials, as well as enable continued development activities of its diagnostics portfolio.

Circadian fell six cents or 11.5 percent to 46 cents.

IMPEDIMED

Impedimed says Richard Carreon has been appointed as the US-based chief executive officer replacing Greg Brown who continues as an executive director in Brisbane.

Mr Brown told Biotech Daily that Mr Carreon would be based at Impedimed's San Diego, California office.

Mr Brown said he would focus on investor relations as well as other operational tasks based in the Brisbane office.

Impedimed he said that Mr Carreon was a former Medtronic senior executive and would begin work at the company's for the company by July 9, 2012, on a base salary of \$US375,000 a year.

The company said that Mr Carreon was with Medtronic for 11 years and was involved in bringing new technologies to market and expanding existing product penetration.

Impedimed said that Mr Carreon has a "strong sales background" as well as leadership in cost management and leverage across business units.

Impedimed chair Dr Cherrell Hirst praised Greg Brown's "excellent work ... since 2003".

Dr Hirst said that for continued growth Impedimed, needed a chief executive officer resident in the US.

Impedimed was up one cent or 3.45 percent to 30 cents.

CRYOSITE

Cryosite chairman Andrew Kroger increased his substantial shareholding in his company from 7,434,276 shares (15.94%) to 9,314,276 shares (19.97%).

The substantial shareholder notice said the 1,880,000 shares were acquired by Andrew Kroger, Daltonvale Pty Ltd and Colfax Bay Pty Ltd at 18 cents a share

Cryosite was untraded at 18 cents.

ATCOR MEDICAL

Atcor has requested a trading halt pending an announcement "in relation to a potential capital raising".

Trading will resume on June 14, 2012 or on an earlier announcement.

Atcor last traded at nine cents.